Literature DB >> 18854672

Acute phosphate nephropathy-an emerging threat.

Yaacov Ori1, Michal Herman, Ana Tobar, Gil Chernin, Uzi Gafter, Avry Chagnac, Ofer Ben Izhak, Asher Korzets.   

Abstract

BACKGROUND: Acute phosphate nephropathy (APN) is a clinicopathological entity causing renal failure, after ingestion of oral sodium phosphate solution (OSPS). Approximately 25 cases have been described, but OSPS is still widely used. This study reports a further 5 cases and discusses the ever-growing significance of APN.
METHODS: Five cases of APN were included, 3 retrospectively whereas 2 were diagnosed prospectively. In all, use of OSPS was established, and other causes of nephrocalcinosis were excluded.
RESULTS: Average age was 67.4 +/- 7.0 years, with a female preponderance (4:1). All patients had hypertension. Baseline serum creatinine: 0.7 to 1.2 mg/dL (creatinine clearance: 52 to 77 mL/min). Time from colonoscopy to presentation was 56 +/- 36 days. Serum creatinine levels at presentation: 1.4 to 3.6 mg/dL. Time from colonoscopy to renal biopsy was 123 +/- 88 days. Urinalysis showed minimal proteinuria, leucocyturia, and hematuria. One patient had renal glucosuria. All patients were anemic (hemoglobin 8.8-11.4 gr/dL). Serum calcium and phosphate were normal. One required hemodialysis. Mean follow-up was 36 +/- 17 months. Serum creatinine levels at end of follow-up were 1.3 to 3.1 mg/dL. Renal function did not recover completely in any patient. Four required long-term erythropoietin treatment. The prominent histopathological findings were calcium-phosphate tubular depositions (100%), interstitial fibrosis (80%), hypertensive changes (80%), and acute tubular degenerative and regenerative changes (60%).
CONCLUSIONS: APN is a serious, irreversible renal complication of OSPS. It is probably under-recognized. Risk factors include female gender, older age, hypertension, and renal failure, although it may occur with preexisting normal renal function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18854672     DOI: 10.1097/MAJ.0b013e318167410c

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  11 in total

1.  A murine model of phosphate nephropathy.

Authors:  Philipp Eller; Kathrin Eller; Alexander H Kirsch; Josef J Patsch; Anna M Wolf; Andrea Tagwerker; Ursula Stanzl; Reinhard Kaindl; Volker Kahlenberg; Gert Mayer; Josef R Patsch; Alexander R Rosenkranz
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 2.  Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism.

Authors:  Makoto Kuro-o
Journal:  Nat Rev Nephrol       Date:  2013-06-18       Impact factor: 28.314

Review 3.  Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism.

Authors:  Ming Chang Hu; Kazuhiro Shiizaki; Makoto Kuro-o; Orson W Moe
Journal:  Annu Rev Physiol       Date:  2013       Impact factor: 19.318

Review 4.  The safety of osmotically acting cathartics in colonic cleansing.

Authors:  Caroline Nyberg; Jakob Hendel; Ole H Nielsen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-08-24       Impact factor: 46.802

5.  Sodium phosphate does not increase risk for acute kidney injury after routine colonoscopy, compared with polyethylene glycol.

Authors:  J Bradley Layton; Philip J Klemmer; Christian F Christiansen; Andrew S Bomback; John A Baron; Robert S Sandler; Abhijit V Kshirsagar
Journal:  Clin Gastroenterol Hepatol       Date:  2014-01-29       Impact factor: 11.382

Review 6.  Contribution of phosphate and FGF23 to CKD progression.

Authors:  Kyle P Jansson; Alan S L Yu; Jason R Stubbs
Journal:  Curr Opin Nephrol Hypertens       Date:  2022-03-11       Impact factor: 3.416

7.  Incidence and outcome of acute phosphate nephropathy in Iceland.

Authors:  Vala Kolbrún Pálmadóttir; Hjalti Gudmundsson; Sverrir Hardarson; Margrét Arnadóttir; Thorvaldur Magnússon; Margrét B Andrésdóttir
Journal:  PLoS One       Date:  2010-10-19       Impact factor: 3.240

8.  Furosemide, orlistat and non-steroidal anti-inflammatory agents-too much for the kidneys to handle!

Authors:  Asher Korzets; Uzi Gafter; Ana Tobar; Avri Chagnac; Boris Zingerman; Yaacov Ori
Journal:  NDT Plus       Date:  2009-01-26

9.  Calcium phosphate microcrystals in the renal tubular fluid accelerate chronic kidney disease progression.

Authors:  Kazuhiro Shiizaki; Asako Tsubouchi; Yutaka Miura; Kinya Seo; Takahiro Kuchimaru; Hirosaka Hayashi; Yoshitaka Iwazu; Marina Miura; Batpurev Battulga; Nobuhiko Ohno; Toru Hara; Rina Kunishige; Mamiko Masutani; Keita Negishi; Kazuomi Kario; Kazuhiko Kotani; Toshiyuki Yamada; Daisuke Nagata; Issei Komuro; Hiroshi Itoh; Hiroshi Kurosu; Masayuki Murata; Makoto Kuro-O
Journal:  J Clin Invest       Date:  2021-08-16       Impact factor: 14.808

Review 10.  A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney disease.

Authors:  Makoto Kuro-O
Journal:  Kidney Int Suppl (2011)       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.